US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% NVDA $216.00 ▲+2.39% META $630.56 ▼-1.88% SPCX $146.90 ▼-0.40% AAPL $343.91 ▼-1.10% MSFT $532.60 ▲+1.54% INTC $90.47 ▲+4.04%
FinancialContent

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

3.790 +0.040 (+1.07%)
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aclaris Therapeutics, Inc. - Common Stock

News headline image
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
Via MarketBeat
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END 
Via FinancialNewsMedia